article · Frontiers in Pediatrics
Introduction Despite the fact that antiretroviral therapy (ART) has reduced HIV/AIDS-related morbidity and mortality, pediatrics treatment failure remains a global concern. As a result, this study set out prudently to determine the prevalence of virologic failure and its predictors among children and adolescents on a Dolutegravir (DTG)-based antiretroviral regimen. Methods A hospital-based retrospective cross-sectional study was conducted on children and adolescents on ART at Debre Tabor Comprehensive Specialized Hospital in Northwest Ethiopia from February-2017 to September-2023. Study participants were selected purposively. Data was collected using a semi-structured questionnaire and a data abstraction tool. Bivariate and multivariate logistic regression analyses were fitted to determine the linked factors. A p -value less than 0.05 was deemed to indicate a statistically significant association. Results Among the 359 children and adolescents included in this study, 38 (10.58%) had developed virological failure. The odds of virological failure among children and adolescents were found to be increased by the age of the child <10 years (AOR = 4.41; 95% CI: 2.60–7.47), the care taker being a guardian or neighbor of patient (AOR = 2.03; 95% CI: 1.15–4.73), both parents passing away (AOR = 1.29; 95% CI: 0.12–2.68), CD4 counts ≤200 cells/µL (AOR = 4.3; 95% CI: 1.32–5.9), being infected with OIs (AOR = 2.03; 95% CI: 1.38–3.55), poor adherence status (AOR = 1.37: 95% CI: 1.12–3.11), adverse drug reaction (AOR = 1.75: 95% CI: 1.02–4.97), and anemic (AOR = 1.70: 95% CI: 1.03–5.15.04). Conclusion Despite potent DTG-based ARTs being introduced, virologic failure remains a concern in the study area. Special consideration should be directed towards children under the age of 10 years who are in the care of a guardian or neighbors, have lost both parents, are infected with opportunistic infections, have a poor adherence status, are experiencing adverse drug reactions, and anemic.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3389/fped.2025.1442215
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.